As solid-organ transplantation has evolved into a highly effective treatment for end-stage organ disease, the long-term health implications of chronic exposure of recipients to immunosuppressants and other pharmacological agents are becoming more apparent. Coronary heart disease has long been known to plague kidney transplant recipients and more recently has been found to affect heart transplant recipients disproportionately. Coronary heart disease after liver transplantation, however, is less well known. The purpose of this study was to examine risk factors for premature coronary heart disease in asymptomatic adult recipients of liver transplants. Nutrition-related risk factors for coronary heart disease (obesity and hyperlipidemia) were measured in 29 patients before and after liver transplantation. Changes with respect to primary immunosuppression protocol (cyclosporine plus corticosteroid vs tacrolimus plus corticosteroid) were compared. Risk factors that had not been present before transplantation were apparent in both groups by 6 months after transplantation. Although obesity and hyperlipidemia were not found to be independent risk factors for coronary heart disease, they were clinically important when considered in combination. Cyclosporine was associated with significantly higher serum lipid concentrations than was tacrolimus.
Get full access to this article
View all access options for this article.
References
1.
BremsJJHiattJRColonnaJOEl-KhouryGQuinonesJJRammingKPZiomekSBusuttilRW. Variables influencing the outcome following orthotopic liver transplantation. Arch Surg. 1987;122:1109–1113.
2.
ShawBWWoodRPStrattaRJPillenTJLangnasAN. Stratifying the causes of death in liver transplant recipients: An approach to improving survival. Arch Surg. 1989;124:895–898.
3.
DeverGEA. Community Health Analysis: Global Awareness at the Local Level. 2nd ed.Gaithersburg, Md: Aspen Publishers Inc, 1991.
4.
IbelsLSAlfreyACWeilR. Hyperlipidemia in adult, pediatric and diabetic renal transplant recipients. Am J Med. 1978;64:634–642.
5.
KeoghASimonsLSprattPEsmoreDChangVHickieJBaronD. Hyperlipidemia after heart transplantation. J Heart Transplant. 1988;7:171–175.
6.
RaineAEGCarterGMannJIMorrisPJ. Adverse effect of cyclosporin on plasma cholesterol in renal transplant recipients. Nephrol Dial Transplant. 1988;3:458–463.
7.
HorlWHRiegelWWannerC. Endocrine and metabolic abnormalities following kidney transplantation. Klin Wochenschr. 1989;67:907–918.
8.
KuoPCKirschenbaumJMGordonJ. Lovastatin therapy for hypercholesterolemia in cardiac transplant recipients. Am J Cardiol. 1989;64:631–635.
9.
LiviUBortolottiGFaggianA. Effects of immunosuppression on glucose and lipid metabolism after heart transplantation. Transplant Proc. 1989;21:2477–2480.
10.
HaganMEHollandCSHerrickCMRasmussenLG. Amelioration of weight gain after heart transplantation by corticosteroid-free maintenance immunosuppression. J Heart Transplant. 1990;9:382–385.
11.
RadovancevicBPoindexterSBirovljevS. Risk factors for development of accelerated coronary artery disease in cardiac transplant recipients. Eur J Cardiothorac Surg. 1990;4:309–312.
12.
WintersGLKendallTJRadioSG. Posttransplant obesity and hyperlipidemia: Major predictors of severity of coronary arteriopathy in failed human heart allografts. J Heart Transplant. 1990;9:364–370.
13.
GradyKLConstanzo-NordinMRHeroldLSSriniavasanSPifarreR. Obesity and hyperlipidemia after heart transplantation. J Heart Lung Transplant. 1991;10:449–454.
14.
HasseJ. Nutritional considerations in liver transplantation. Top Clin Nutr. 1991;7:24–33.
15.
MunozSJDeemsMJMoritzMJMartinPJarrellBEMaddreyWC. Hyperlipidemia and obesity after orthotopic liver transplantation. Transplant Proc. 1991;23:1480–1483.
16.
PalmerMSchaffnerFThungSN. Excessive weight gain after liver transplantation. Transplantation. 1991;51:797–799.
17.
PirschJDAmbrustMJKnechtleSJ. Effect of steroid withdrawal on hypertension and cholesterol levels in living related recipients. Transplant Proc. 1991;23:1363–1364.
18.
VathsalaAWeinbergRBSchoenbergL. Lipid abnormalities in cyclosporine-prednisone-treated renal transplant recipients. Transplantation. 1991;48:37–43.
19.
GonyeaJE. Weight change and serum lipoptroteins in recipients of renal allografts. Mayo Clin Proc. 1992;67:653–657.
20.
MatheDAdamRMalmendierC. Prevalence of dyslipidemia in liver transplant recipients. Transplantation. 1992;54:167–170.
21.
CattranDCSteinerGWilsonDRFentonSSA. Hyperlipidemia after renal transplantation: Natural history and pathophysiology. Ann Intern Med. 1979;91:554–559.
22.
GunnarssonRLofmarkRNordlanderRNyquistOGrothC-G. Acute myocardial infarction in renal transplant recipients: Incidence and prognosis. Eur Heart J. 1984;5:218–221.
23.
KasiskeBLUmenAJ. Persistent hyperlipidemia in renal transplant patients. Medicine. 1987;66:309–316.
24.
JevnikarAMPetricRHolubBJPhilbrickDJClarkWK. Effect of cyclosporine on plasma lipids and modification with dietary fish oil. Transplantation. 1988;46:722–725.
25.
KasiskeBL. Risk factors for accelerated atherosclerosis in renal transplant recipients. Am J Med. 1988;84:985–982.
26.
BallantyneCMPodetEJPatschWP. Effects of cyclosporine therapy on plasma lipoprotein levels. JAMA. 1989;262:53–56.
27.
VathsalaAWeinbergRBSchoenbergL. Lipid abnormalities in renal transplant recipients treated with cyclosporine. Transplant Proc. 1989;21:3670–3673.
28.
DivakarDBaileyRRFramptonCMGeorgePMWalmsleyTAMurphyJ. Hyperlipidemia in stable renal transplant recipients. Nephron. 1991;59:423–428.
29.
DruekeTBAbdulmassihZLacourBBaderCChevalierAKreisH. Atherosclerosis and lipid disorders after renal transplantation. Kidney Int. 1991;39(suppl. 31):S24–S28.
30.
MunozSJ. Hyperlipidemia and other coronary risk factors after orthotopic liver transplantation: Pathogenesis, diagnosis, and management. Liver Transplant Surg. 1995;1(suppl 1):29–38.
31.
BittarAERatcliffePJRichardsonAJ. The prevalence of hyperlipidemia in renal transplant recipients: Associations with immunosuppressants and antihypertensive therapy. Transplantation. 1990;50:987–992.
32.
PalomboJDLopesSMZeiselSH. Effectiveness of orthotopic liver transplantation on the restoration of cholesterol metabolism in patients with end-stage liver disease. Gastroenterology. 1987;93:1170–1171.
33.
PonticelliCBarbiGLCantaluppiAPCegliaE. Hyperlipidemia after renal transplantation. Lancet. 1975;1:1090–1091.
34.
PonticelliCBarbiGLCantaluppiA. Lipid disorders in renal transplant recipients. Nephron. 1975;20:189–190.
35.
ChanMKVargheseZPersaudJWFernandoONMoorheadJF. The role of multiple pharmacotherapy in the pathogenesis of hyperlipidemia after renal transplantation. Clin Nephrol. 1981;15:309–313.
36.
IbelsLSSimonsLAKingJOWilliamsPFNealeFCStewartJH. Studies on the nature and causes of hyperlipidemia in uraemia, maintenance dialysis and renal transplantation. Q J Med. 1981;50:149–160.
37.
RenlundDGBristowMRCrandallBG. Hypercholesterolemia after heart transplantation: Amelioration by corticosteroid-free maintenance immunosuppression. J Heart Transplant. 1989;8:214–220.
38.
HodelKMordasiniR-CBrunnerFLandmannJThielG. Cyclosporin A (CYA) and hyperlipidemia after renal transplantation. Kidney Int. 1984;25:984–985.
39.
HarrisKPGRussellGIParvinSDVeitchPSWallsJ. Alterations in lipid and carbohydrate metabolism attributable to cyclosporin A in renal transplant recipients. BMJ. 1986;292:16.
40.
HessMLHastilloAThompsonJA. Lipid mediators in organ transplantation: Does cyclosporine accelerate coronary atherosclerosis?Transplant Proc. 1985;19(Suppl):71S–73S.
41.
StovinPGIEnglishTAH. Effects of cyclosporine on the transplanted human heart. J Heart Transplant. 1987;6:180–185.
42.
VersluisDJWentingGJDerkxFHMSchalecampMADHJeekelJ. Who should be converted from cyclosporine to conventional immunosuppression in kidney transplantation, and why. Transplantation. 1987;44:387–389.
43.
StamlerJSVaughnDERuddA. Frequency of hypercholesterolemia after cardiac transplantation. Am J Cardiol. 1988;62:1268–1272.
44.
JevnikarAMPetricRHolubBJPhilbrickDJClarkWF. Effect of cyclosporine on plasma lipids and modification with dietary fish oil. Transplantation. 1989;46:722–725.
45.
DeGroenPC. Cyclosporine, low-density lipoproteins, and cholesterol. Mayo Clin Proc. 1988;63:1012–1021.
46.
National Center for Health Statistics. NHANES 1976–1980. Washington, DC: Public Health Service, Department of Health and Human Services, 1981. PHS Publication No. PHS 81-1317.
47.
Department of Health and Human Services, National Center for Health Statistics. National Health and Nutrition Examination Survey II 1980. Washington, DC: US Government Printing Office, 1980.
48.
BrayGA. Overweight is risking fate: Definition, classification, prevalence, and risks. Ann N Y Acad Sci. 1989;499:14–28.
49.
BrayG. Pathophysiology of obesity. Am J Clin Nutr. 1992;55(Suppl.):488S–494S.
50.
FriedewaldWTLevyRIFredricksonDS. Estimation of the concentration of low density lipoprotein in plasma with use of preparative ultracentrifuge. Clin Chem. 1972;18:449–502.
51.
The Expert Panel. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Arch Intern Med. 1988;148:36–69.
52.
KaplanNM. The deadly quartet. Upper body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med. 1989;149:1514–1520.
